$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414028653 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$2.425M	$6.696M	$3.568M
YoY Change	7.11%	87.67%	-7.59%
Cost Of Revenue	$1.605M	$4.073M	$971.0K
YoY Change	21.78%	319.46%	-26.44%
Gross Profit	$1.081M	$3.310M	$2.997M
YoY Change	-38.09%	10.44%	24.46%
Gross Profit Margin	44.58%	49.43%	84.0%
Selling, General & Admin	$1.566M	$3.711M	$2.103M
YoY Change	-28.23%	76.46%	29.02%
% of Gross Profit	144.87%	112.11%	70.17%
Research & Development	$7.076M	$8.152M	$7.754M
YoY Change	-11.44%	5.13%	-12.35%
% of Gross Profit	654.58%	246.28%	258.73%
Depreciation & Amortization	$800.0K	$828.0K	$930.0K
YoY Change	-10.11%	-10.97%	0.0%
% of Gross Profit	74.01%	25.02%	31.03%
Operating Expenses	$8.642M	$11.86M	$9.857M
YoY Change	-15.04%	20.35%	11.42%
Operating Profit	-$5.447M	-$6.468M	-$4.429M
YoY Change	-20.99%	46.04%	-26.97%
Interest Expense	-$670.0K	-$880.0K	$110.0K
YoY Change	-1216.67%	-900.0%	-31.25%
% of Operating Profit
Other Income/Expense, Net	-$672.0K	-$877.0K	$108.0K
YoY Change	-1278.95%	-912.04%
Pretax Income	-$6.120M	-$7.350M	-$4.320M
YoY Change	-10.53%	70.14%	-26.78%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.119M	-$7.345M	-$4.321M
YoY Change	-10.5%	69.98%	-26.81%
Net Earnings / Revenue	-252.33%	-109.69%	-121.1%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.66	-$0.79	-$0.47
COMMON SHARES
Basic Shares Outstanding	93.61M shares	93.58M shares	93.50M
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.10M	$77.70M	$41.90M
YoY Change	114.8%	85.44%	-8.11%
Cash & Equivalents	$71.14M	$77.69M	$41.87M
Short-Term Investments
Other Short-Term Assets	$2.000M	$2.600M	$3.600M
YoY Change	-44.44%	-27.78%
Inventory	$7.135M	$6.527M	$5.773M
Prepaid Expenses
Receivables	$2.097M	$1.735M	$1.698M
Other Receivables	$1.988M	$2.609M	$3.553M
Total Short-Term Assets	$82.36M	$88.56M	$52.89M
YoY Change	79.32%	67.43%	6.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.44M	$13.10M	$15.71M
YoY Change	-17.09%	-16.6%	-10.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.800M	$1.800M	$1.300M
YoY Change	28.57%	38.46%	18.18%
Total Long-Term Assets	$14.29M	$14.86M	$17.05M
YoY Change	-12.75%	-12.86%	-8.48%
TOTAL ASSETS
Total Short-Term Assets	$82.36M	$88.56M	$52.89M
Total Long-Term Assets	$14.29M	$14.86M	$17.05M
Total Assets	$96.65M	$103.4M	$69.94M
YoY Change	55.12%	47.86%	2.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.600M	$4.600M	$3.800M
YoY Change	-7.69%	21.05%	-17.39%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.18M	$26.78M	$24.41M
YoY Change	2.07%	9.72%	37.71%
LONG-TERM LIABILITIES
Long-Term Debt			$2.700M
YoY Change
Other Long-Term Liabilities	$42.00M	$43.10M	$51.80M
YoY Change	-11.95%	-16.8%	821.22%
Total Long-Term Liabilities	$109.3M	$110.2M	$51.82M
YoY Change	129.23%	112.7%	-9.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.18M	$26.78M	$24.41M
Total Long-Term Liabilities	$109.3M	$110.2M	$51.82M
Total Liabilities	$136.4M	$137.0M	$76.23M
YoY Change	83.66%	79.72%	1.74%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$39.79M	-$33.58M	-$6.283M
YoY Change
Total Liabilities & Shareholders Equity	$96.65M	$103.4M	$69.94M
YoY Change	55.12%	47.86%	2.16%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$6.119M	-$7.345M	-$4.321M
YoY Change	-10.5%	69.98%	-26.81%
Depreciation, Depletion And Amortization	$800.0K	$828.0K	$930.0K
YoY Change	-10.11%	-10.97%	0.0%
Cash From Operating Activities	-$6.520M	-$8.340M	-$9.586M
YoY Change	-19.61%	-13.0%	52.62%
INVESTING ACTIVITIES
Capital Expenditures	$110.0K	$263.0K	$642.0K
YoY Change	-84.29%	-59.03%	-20.74%
Acquisitions
YoY Change
Other Investing Activities	-$80.00K	$50.00K	$47.00K
YoY Change	300.0%	6.38%	11.9%
Cash From Investing Activities	-$200.0K	-$370.0K	-$689.0K
YoY Change	-72.22%	-46.3%	-19.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	30.00K
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-6.520M	-8.340M	-$9.586M
Cash From Investing Activities	-200.0K	-370.0K	-$689.0K
Cash From Financing Activities	0.000	30.00K
Net Change In Cash	-6.720M	-8.680M	-$10.28M
YoY Change	-23.64%	-15.52%	-155.72%
FREE CASH FLOW
Cash From Operating Activities	-$6.520M	-$8.340M	-$9.586M
Capital Expenditures	$110.0K	$263.0K	$642.0K
Free Cash Flow	-$6.630M	-$8.603M	-$10.23M
YoY Change	-24.74%	-15.89%	44.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93606460	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
CY2014Q1	dei	Trading Symbol TradingSymbol	PLX
CY2014Q1	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	12000	USD
CY2013Q1	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	28000	USD
CY2014Q1	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	828000	USD
CY2013Q1	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	926000	USD
CY2014Q1	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	1000	USD
CY2013Q1	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	19000	USD
CY2014Q1	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	2085000	USD
CY2013Q1	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	2431000	USD
CY2014Q1	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	138000	USD
CY2013Q1	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	815000	USD
CY2014Q1	plx	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2014Q1	plx	Other Gains Losses OtherGainsLosses	687000	USD
CY2013Q1	plx	Other Gains Losses OtherGainsLosses	400000	USD
CY2014Q1	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	6067000	USD
CY2013Q1	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	5323000	USD
CY2014Q1	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	508000	USD
CY2013Q1	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	1020000	USD
CY2014Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	14533000	USD
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	12073000	USD
CY2014Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4639000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5254000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1735000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2091000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	162000	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	347000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	109000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18913153	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7471571	shares
CY2014Q1	us-gaap	Assets Assets	103416000	USD
CY2013Q4	us-gaap	Assets Assets	113333000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	88561000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	97903000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77690000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86398000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41870000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8708000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10165000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67151000	USD
CY2013Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67048000	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	4073000	USD
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	971000	USD
CY2014Q1	us-gaap	Deferred Costs DeferredCosts	135000	USD
CY2013Q4	us-gaap	Deferred Costs DeferredCosts	141000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7609000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9369000	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	40655000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	41796000	USD
CY2014Q1	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1622000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1578000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.08
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.05
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5523000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	6527000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	7957000	USD
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2076000	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-29000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	110000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-14000	USD
CY2013Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	78000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	3310000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	2997000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-450000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3005000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	744000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2901000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2740000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1430000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1734000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	57000	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4281000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2342000	USD
CY2014Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	170000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	92000	USD
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	1100000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	136994000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	140279000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103416000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113333000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26781000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26696000	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	110213000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	113583000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2371000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	31000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations		USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-370000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-689000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8340000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9586000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-7345000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-4321000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-877000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	108000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6468000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4429000	USD
CY2014Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	915000	USD
CY2013Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	14000	USD
CY2014Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	38000	USD
CY2013Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	122000	USD
CY2014Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2609000	USD
CY2013Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1457000	USD
CY2014Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	50000	USD
CY2013Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	47000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	263000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	642000	USD
CY2014Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2407000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2368000	USD
CY2014Q1	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	50000	USD
CY2013Q1	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	60000	USD
CY2009Q4	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	3500000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13098000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13711000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8152000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7754000	USD
CY2014Q1	us-gaap	Revenues Revenues	6696000	USD
CY2013Q1	us-gaap	Revenues Revenues	3568000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3711000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2103000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	670000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1367000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-33578000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-26946000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3357000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-6283000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92686638	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92184220	shares

Files In Submission

Name	View Source	Status
0001144204-14-028653-index-headers.html	Edgar Link	pending
0001144204-14-028653-index.html	Edgar Link	pending
0001144204-14-028653.txt	Edgar Link	pending
0001144204-14-028653-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
plx-20140331.xml	Edgar Link	completed
plx-20140331.xsd	Edgar Link	pending
plx-20140331_cal.xml	Edgar Link	unprocessable
plx-20140331_def.xml	Edgar Link	unprocessable
plx-20140331_lab.xml	Edgar Link	unprocessable
plx-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v376666_10q.htm	Edgar Link	pending
v376666_ex10-1.htm	Edgar Link	pending
v376666_ex10-2.htm	Edgar Link	pending
v376666_ex10-3.htm	Edgar Link	pending
v376666_ex31-1.htm	Edgar Link	pending
v376666_ex31-2.htm	Edgar Link	pending
v376666_ex32-1.htm	Edgar Link	pending
v376666_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2014 Q2 Form 10-Q Financial Statement

#000114420414028653 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2014 Q2 Form 10-Q Financial Statement

#000114420414028653 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx